- Poster presentation
- Open Access
P87 - A national multicenter registration of treatment with omalizumab in Danish asthmatic children
Clinical and Translational Allergy volume 4, Article number: P142 (2014)
In Denmark, Omalizumab is approved for treating children with severe persistent allergic asthma older than 6 years of age. No systematic registration of the efficacy in the Danish child population according to asthma symptoms or the efficacy on co-morbid allergic symptoms exists. A broad panel of outcome measures is necessary to evaluate the efficacy of Omalizumab treatment.
To provide a standardized systematic registration in order to create a database enrolling children with severe allergic asthma treated with Omalizumab.
Method and study design
A national multicenter registration and follow-up study based on children with clinical persistent severe allergic asthma including both retrospective and prospective registration.
Children, 6-18 years of age, with severe persistent allergic asthma according to GINA treated with Omalizumab.
A broad panel of outcome measures is scheduled at baseline and during treatment:
Quality of life score. (Juniper)
Rhinitis score, R-RTSS
The monitoring plan and follow-up programme will be presented in a flowchart.
We believe that a national systematic registration will increase knowledge regarding efficacy of Omalizumab treatment in this rare group of severe allergic asthmatic children.
About this article
Cite this article
Spangenberg, K.B., Jørgensen, I.M., Halken, S. et al. P87 - A national multicenter registration of treatment with omalizumab in Danish asthmatic children. Clin Transl Allergy 4, P142 (2014). https://doi.org/10.1186/2045-7022-4-S1-P142
- Asthmatic Child
- Allergic Asthma
- Asthma Exacerbation